drugset

drugset / Trial / NCT03184753

Genetically Modified T Cells Against Ovarian Cancer

NCT03184753 ↗

Phase 1/2 Recruiting 100 enrolled Shenzhen Geno-Immune Medical Institute

NaSingle-groupOpen-labelTreatment

Summary

The primary objectives are to evaluate the safety and efficacy of infusion of autologous ovarian cancer immunogene-modified T cells (OC-IgT cells).

Timeline

Start: 2025-05-01
Primary completion: 2028-09-30
Completion: 2029-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OC-IgT cells	Cell therapy	—	Intravenous

Indications